{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/26323431"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "ical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Amgen???s decisions with respect to the design, initiation, conduct, timing and continuation of development activities for omecamtiv mecarbil; Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing nece" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "rascalsfoundation.org" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/356843920"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/26323431" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/380368426"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/26323431"] } } }
